Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 7/20 | 0.46 |
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703529 | 0.95 | LTA4H (0.55) | LTA4HELANECNR1CNR2NR5A1 | |
| SCHEMBL14382257 | 0.92 | PTGS2 (0.51) | LTA4HELANECNR1CNR2SLC5A1 | |
| SCHEMBL17534301 | 0.90 | CNR1 (0.51) | LTA4HCNR1CNR2NR5A1PLA2G2A | |
| SCHEMBL7307689 | 0.88 | LTA4H (0.59) | LTA4HCNR1CNR2NR5A1PLA2G2A | |
| SCHEMBL17534007 | 0.88 | LTA4H (0.46) | LTA4HELANECNR1CNR2NR5A1 | |
| SCHEMBL91974 | 0.87 | LTA4H (0.48) | LTA4HELANEPLA2G2APTGS1PTGS2 | |
| SCHEMBL17204428 | 0.87 | ELANE (0.54) | LTA4HELANECNR1CNR2NR5A1 | |
| SCHEMBL17534017 | 0.87 | CNR1 (0.56) | CNR1CNR2NR5A1PLA2G2A | |
| SCHEMBL25612264 | 0.86 | LTA4H (0.47) | LTA4HELANECNR1CNR2NR5A1 | |
| SCHEMBL17540924 | 0.85 | CNR1 (0.48) | LTA4HCNR1CNR2NR5A1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504380-A | Liquid stabilizer for nitrate compound and preparation method thereof | 南京理工大学 | 2025-02-25 | — | — | CN | disclosed |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2016033416-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033416-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | WO | disclosed |
| EP-1751127-B1 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | INTERMED DISCOVERY GMBH (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1751127-A2 | NOVEL CYLOPENTA¬B|BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005113529-A2 | NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF | BAYER HEALTHCARE AG (DE) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | LTA4H 2757/4885ELANE 4183/4885CNR1 335/4885 |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BRDT, BRPF3, BRWD1 | LTA4H 3000/4885ELANE 856/4885CNR1 3430/4885 |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | FKBP1A, FKBP2, FKBP1B | LTA4H 1308/4885ELANE 452/4885CNR1 397/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | LTA4H 2757/4885ELANE 4183/4885CNR1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.